As­traZeneca snips IL-12 can­di­date from pipeline as it sharp­ens I/O fo­cus

Tip­ping its hand as part of its quar­ter­ly R&D up­date, As­traZeneca re­port­ed it has dropped two ear­ly-stage can­cer drugs and a mid-stage can­di­date for chron­ic ob­struc­tive pul­monary dis­ease, while al­so ditch­ing some tri­als for Fasen­ra and an ex­per­i­men­tal IL-33 an­ti­body.

The de­ci­sion to dis­card an IL-12 ther­a­py that works by de­liv­er­ing an IL-12 trans­gene with­in an on­colyt­ic virus comes just days af­ter Bris­tol My­ers Squibb an­nounced it’s hand­ing back an IL-12 can­di­date to Drag­on­fly. But ac­cord­ing to As­traZeneca, it’s all about pri­or­i­tiz­ing the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER